GPRC5A and adenocarcinoma: The incidence of tumors increased with time in the NNK-treated Gprc5a−/− mice reaching 50% and 83% for adenomas and adenocarcinomas, respectively at 18 months compared to 16.7% and 16.7%, respectively in the control mice (Fig. 2).